The emergence of next-generation KRAS G12C inhibitors has led Verastem Oncology to change course. | The emergence of ...

Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...

The EVEREST-2 study reported the first complete response to CAR-T cell therapy in a non-small cell lung cancer patient.

Black Diamond Therapeutics Inc. (NASDAQ:BDTX) is one of the best biotech penny stocks to buy according to analysts. On ...

Top articles in non–small cell lung cancer (NSCLC) include FDA approvals, improved outcomes due to certain treatments, and ...

Verastem, Inc. shifts focus to VS-7375 for KRAS G12D tumors after ending RAMP-203. Click to learn about VSTM's key catalysts ...

Among survivors of non-small cell lung cancer, nearly 8% developed non-lung secondary cancers over about 6 years, and this risk may be driven by genetic factors.

The National Institute for Health and Care Excellence (NICE) has recommended amivantamab (Rybrevant) plus lazertinib ...

Researchers headed by a team at Keck Medicine of USC have found that corticosteroids, which are commonly prescribed to non-small cell lung cancer (NSCLC) patients to alleviate cancer-related symptoms, ...

Martin Dietrich, MD, PhD, a medical oncologist at the Cancer Care Centers of Brevard and an assistant professor at the University of Central Florida, discussed how the recent approval of amivantamab ...

Denmark's Genmab has decided not to continue the development of a drug for cancer, acasunlimab, which had reached phase 3 testing, after a review of its medicines pipeline. The decision to end the ...